OMEROS CORP
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
WA
Business Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119
Mailing Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA, 98119
Phone
206-676-5000
Fiscal Year End
1231
EIN
911663741
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 1, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 14, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Strategic sale of zaltenibart to Novo Nordisk for $75M upfront plus up to $555M in milestones.
- Successful debt restructuring, pushing major repayments to 2029 to extend operational runway.
Insider Trading
SELL
1 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.